EP3365330A4 - Pharmacophores, composés et procédés ayant une application dans le traitement du cancer par inhibition de cyp17a1 et cyp19a1 - Google Patents

Pharmacophores, composés et procédés ayant une application dans le traitement du cancer par inhibition de cyp17a1 et cyp19a1 Download PDF

Info

Publication number: EP3365330A4
Authority: EP; European Patent Office
Prior art keywords: cyp19a1; cyp17a1; pharmacophores; inhibition; cancer
Prior art date: 2015-10-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP16858474.6A

Other languages

German (de)

English (en)

Other versions

EP3365330A1 (fr

EP3365330C0 (fr

EP3365330B1 (fr

Inventor

Njabulo Joyfull GUMEDE

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mangosuthu University Of Technology

Original Assignee

Mangosuthu University Of Technology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-22

Filing date

2016-10-22

Publication date

2019-06-05

2016-10-22 Application filed by Mangosuthu University Of Technology filed Critical Mangosuthu University Of Technology

2018-08-29 Publication of EP3365330A1 publication Critical patent/EP3365330A1/fr

2019-06-05 Publication of EP3365330A4 publication Critical patent/EP3365330A4/fr

2023-06-07 Application granted granted Critical

2023-06-07 Publication of EP3365330C0 publication Critical patent/EP3365330C0/fr

2023-06-07 Publication of EP3365330B1 publication Critical patent/EP3365330B1/fr

Status Active legal-status Critical Current

2036-10-22 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/10—Ontologies; Annotations
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/20—Heterogeneous data integration
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/30—Data warehousing; Computing architectures

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Physics & Mathematics (AREA)
Theoretical Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Spectroscopy & Molecular Physics (AREA)
Medical Informatics (AREA)
Evolutionary Biology (AREA)
Bioinformatics & Computational Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Databases & Information Systems (AREA)
Bioethics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

EP16858474.6A 2015-10-22 2016-10-22 Pharmacophores, composés et procédés ayant une application dans le traitement du cancer par inhibition de cyp17a1 et cyp19a1 Active EP3365330B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ZA201507849		2015-10-22
PCT/ZA2016/050041 WO2017070718A1 (fr)	2015-10-22	2016-10-22	Pharmacophores, composés et procédés ayant une application dans le traitement du cancer par inhibition de cyp17a1 et cyp19a1

Publications (4)

Publication Number	Publication Date
EP3365330A1 EP3365330A1 (fr)	2018-08-29
EP3365330A4 true EP3365330A4 (fr)	2019-06-05
EP3365330C0 EP3365330C0 (fr)	2023-06-07
EP3365330B1 EP3365330B1 (fr)	2023-06-07

Family

ID=58558168

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP16858475.3A Active EP3365819B1 (fr)	2015-10-22	2016-10-22	Pharmacophores, composés et procédés ayant une application dans le traitement du cancer par inhibition de cyp17a1 et cyp19a1
EP16858474.6A Active EP3365330B1 (fr)	2015-10-22	2016-10-22	Pharmacophores, composés et procédés ayant une application dans le traitement du cancer par inhibition de cyp17a1 et cyp19a1

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP16858475.3A Active EP3365819B1 (fr)	2015-10-22	2016-10-22	Pharmacophores, composés et procédés ayant une application dans le traitement du cancer par inhibition de cyp17a1 et cyp19a1

Country Status (6)

Country	Link
US (2)	US11548860B2 (fr)
EP (2)	EP3365819B1 (fr)
CN (2)	CN108779085B (fr)
CA (2)	CA3002570A1 (fr)
WO (2)	WO2017070719A2 (fr)
ZA (2)	ZA201803198B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3093260A1 (fr) *	2018-03-05	2019-09-12	The Board Of Trustees Of The Leland Stanford Junior University	Apprentissage automatique et procedes bases sur une simulation moleculaire pour ameliorer la prevision de liaison et d'activite
CN112533941A (zh)	2018-03-05	2021-03-19	斯坦福大学托管董事会	用于空间图卷积的系统和方法及其在药物发现和分子模拟中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008028617A1 (fr) *	2006-09-06	2008-03-13	F. Hoffmann-La Roche Ag	Dérivés hétéroaryles utilisés en tant qu'inhibiteurs de protéine kinase
US20110178065A1 (en) *	2010-01-15	2011-07-21	Biomarin Pharmaceutical Inc.	Novel cyp17 inhibitors
WO2012143725A1 (fr) *	2011-04-21	2012-10-26	Astex Therapeutics Limited	Composés hétérocycliques bicycliques et leurs utilisations thérapeutiques
WO2015048311A1 (fr) *	2013-09-25	2015-04-02	Cortendo Ab (Publ)	Nouveaux analogues de 5-(phénoxyméthyl)-1,3-dioxane fonctionnalisés présentant une action inhibitrice du cytochrome p450

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0574992A1 (fr)	1992-06-17	1993-12-22	Glaxo Group Limited	Dérivés de 5(1,2,4-triazol-1-ylméthyl)-3H-isobenzofuran-1-one, leurs préparation et application en tant qu'inhibiteurs d'aromatase
US6564152B2 (en) *	2000-01-26	2003-05-13	Pfizer Inc	Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists
CN102592040B (zh) *	2002-07-24	2016-12-21	基德姆生物科学有限公司	药物发现的方法
CN1878769A (zh) *	2003-09-11	2006-12-13	凯米亚公司	细胞因子抑制剂
FR2860235A1 (fr) *	2003-09-29	2005-04-01	Yang Ji Chemical Company Ltd	Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
ES2401550T3 (es) *	2008-02-28	2013-04-22	Merck Patent Gmbh	Inhibidores de proteína cinasa y uso de los mismos
WO2012130165A1 (fr) *	2011-03-31	2012-10-04	中国科学院上海生命科学研究院	Marqueur de diagnostic du cancer du foie et utilisation associée
CN102432670B (zh) *	2011-11-29	2013-07-10	浙江省农业科学院	蚕蛹蛋白源二肽ss及其用途
CA2859986A1 (fr) *	2011-12-22	2013-06-27	Tokai Pharmaceuticals, Inc.	Methodes et compositions pour la polytherapie a l'aide d'inhibiteurs de p13k/mtor
CN103425859A (zh) *	2012-05-24	2013-12-04	北京化工大学	一种ttr小分子抑制剂的筛选方法
CA2888161A1 (fr) *	2012-10-15	2014-04-24	Chamaeleo Pharma Bvba	Fosfestrol pour utilisation dans le traitement curatif ou palliatif du cancer de la prostate
CN103655556B (zh) *	2013-11-13	2015-05-13	陈志南	小分子化合物ag-4的抗炎应用
WO2015112369A1 (fr) *	2014-01-24	2015-07-30	Cortendo Ab (Publ)	Nouveaux inhibiteurs du cytochrome p450 et leur méthode d'utilisation
CN104293877B (zh) *	2014-09-28	2016-05-25	山东大学	一种gpr120激动剂的快速筛选方法

2016
- 2016-10-22 WO PCT/ZA2016/050042 patent/WO2017070719A2/fr active Application Filing
- 2016-10-22 CN CN201680071241.2A patent/CN108779085B/zh active Active
- 2016-10-22 US US15/769,824 patent/US11548860B2/en active Active
- 2016-10-22 CA CA3002570A patent/CA3002570A1/fr not_active Abandoned
- 2016-10-22 CN CN201680071222.XA patent/CN108701171B/zh active Active
- 2016-10-22 EP EP16858475.3A patent/EP3365819B1/fr active Active
- 2016-10-22 WO PCT/ZA2016/050041 patent/WO2017070718A1/fr active Application Filing
- 2016-10-22 CA CA3002567A patent/CA3002567C/fr active Active
- 2016-10-22 EP EP16858474.6A patent/EP3365330B1/fr active Active
- 2016-10-22 US US15/769,831 patent/US20200247794A1/en not_active Abandoned
2018
- 2018-05-15 ZA ZA2018/03198A patent/ZA201803198B/en unknown
- 2018-05-15 ZA ZA2018/03199A patent/ZA201803199B/en unknown

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008028617A1 (fr) *	2006-09-06	2008-03-13	F. Hoffmann-La Roche Ag	Dérivés hétéroaryles utilisés en tant qu'inhibiteurs de protéine kinase
US20110178065A1 (en) *	2010-01-15	2011-07-21	Biomarin Pharmaceutical Inc.	Novel cyp17 inhibitors
WO2012143725A1 (fr) *	2011-04-21	2012-10-26	Astex Therapeutics Limited	Composés hétérocycliques bicycliques et leurs utilisations thérapeutiques
WO2015048311A1 (fr) *	2013-09-25	2015-04-02	Cortendo Ab (Publ)	Nouveaux analogues de 5-(phénoxyméthyl)-1,3-dioxane fonctionnalisés présentant une action inhibitrice du cytochrome p450

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017070718A1 *

Also Published As

Publication number	Publication date
EP3365330A1 (fr)	2018-08-29
WO2017070719A2 (fr)	2017-04-27
CN108779085A (zh)	2018-11-09
ZA201803199B (en)	2022-04-28
EP3365819B1 (fr)	2023-06-07
US11548860B2 (en)	2023-01-10
CN108779085B (zh)	2022-03-22
US20200247764A1 (en)	2020-08-06
EP3365819C0 (fr)	2023-06-07
US20200247794A1 (en)	2020-08-06
ZA201803198B (en)	2022-04-28
EP3365819A2 (fr)	2018-08-29
WO2017070719A3 (fr)	2017-08-03
CA3002570A1 (fr)	2017-04-27
CN108701171A (zh)	2018-10-23
CA3002567A1 (fr)	2017-04-27
EP3365330C0 (fr)	2023-06-07
CA3002567C (fr)	2023-07-25
CN108701171B (zh)	2022-06-10
WO2017070718A1 (fr)	2017-04-27
EP3365330B1 (fr)	2023-06-07
EP3365819A4 (fr)	2019-07-24
WO2017070718A4 (fr)	2017-06-15

Publication	Publication Date	Title
EP3302442A4 (fr)	2019-02-06	Formes galéniques et leur utilisation
EP3325473A4 (fr)	2019-06-26	Composés et leurs utilisations dans le traitement de cancers et d'autres états médicaux
HK1256283A1 (zh)	2019-09-20	治療癌症有用的二氫咪唑並吡嗪酮衍生物
EP3359168A4 (fr)	2019-08-07	Composés thérapeutiques et procédés
IL259246A (en)	2018-07-31	Preparations containing pharmaceutical substances and methods of using them
EP3307329A4 (fr)	2019-05-15	Traitement et diagnostic du cancer
EP3408344A4 (fr)	2019-07-10	Procédés et compositions de traitement de puits
HK1243997B (zh)	2020-06-26	Kv1．3抑制劑及其醫學應用
EP3157336A4 (fr)	2018-01-24	Oxabicycloheptanes et oxabicycloheptènes pour le traitement du cancer des ovaires
EP3347025A4 (fr)	2019-04-24	Méthodes et compositions pour le traitement du cancer
IL266486A (en)	2019-07-31	Pharmaceutical preparations and methods for cancer treatment
IL252897A0 (en)	2017-08-31	Indanyl compounds, pharmaceutical preparations and their medical uses
EP3185910A4 (fr)	2018-01-10	Méthodes et compositions pour le traitement du cancer
EP3110902A4 (fr)	2017-10-18	Procédés et fluides de traitement de puits
EP3413906A4 (fr)	2019-10-16	Compositions de combinaison de traitement du cancer, procédés et utilisations
EP3452044A4 (fr)	2020-04-22	Compositions et méthodes pour le traitement du cancer
IL265824A (en)	2019-06-30	Methods and pharmaceutical compositions for the treatment of kidney cancer
EP3337784A4 (fr)	2019-04-17	Utilisation d'uréidomustine (bo-1055) dans le traitement du cancer
EP3220955A4 (fr)	2018-07-25	Compositions pour le traitement de la douleur aiguë, post-opératoire ou chronique, et leurs procédés d'utilisation
ZA201803199B (en)	2022-04-28	Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of cyp17a1 and cyp19a1
EP3380468B8 (fr)	2020-11-04	Composés de bis-pyridazine et leur utilisation dans le traitement du cancer
IL249860A0 (en)	2017-03-30	Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
EP3131545C0 (fr)	2024-05-29	Utilisation d'énoximone pour le traitement d'affections topiques associées au système immunitaire, dans des compositions pharmaceutiques ainsi que dans des préparations pharmaceutiques
HK1243998A1 (zh)	2018-07-27	Kv1．3抑制劑及其醫學應用
EP3377113A4 (fr)	2019-06-19	Compositions et procédé de traitement et de dépistage du cancer du côlon

Legal Events

Date	Code	Title	Description
2017-04-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-07-27	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-07-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-08-29	17P	Request for examination filed	Effective date: 20180521
2018-08-29	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-08-29	AX	Request for extension of the european patent	Extension state: BA ME
2019-01-30	DAV	Request for validation of the european patent (deleted)
2019-01-30	DAX	Request for extension of the european patent (deleted)
2019-06-05	A4	Supplementary search report drawn up and despatched	Effective date: 20190506
2019-06-05	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/18 20060101ALI20190429BHEP Ipc: C07C 235/56 20060101ALI20190429BHEP Ipc: C07D 417/12 20060101ALI20190429BHEP Ipc: A61K 31/167 20060101ALI20190429BHEP Ipc: C07C 311/29 20060101ALI20190429BHEP Ipc: A61P 35/00 20060101ALI20190429BHEP Ipc: A61K 31/427 20060101ALI20190429BHEP Ipc: C07D 405/12 20060101ALI20190429BHEP Ipc: A61K 31/351 20060101ALI20190429BHEP Ipc: A61K 31/4196 20060101ALI20190429BHEP Ipc: C07D 413/12 20060101ALI20190429BHEP Ipc: C07D 405/14 20060101ALI20190429BHEP Ipc: C07D 495/04 20060101ALI20190429BHEP Ipc: C07D 279/16 20060101ALI20190429BHEP Ipc: C07D 309/34 20060101ALI20190429BHEP Ipc: C07D 249/12 20060101ALI20190429BHEP Ipc: C07D 231/56 20060101ALI20190429BHEP Ipc: C07D 401/14 20060101ALI20190429BHEP Ipc: C07D 265/36 20060101AFI20190429BHEP Ipc: C07C 237/20 20060101ALI20190429BHEP Ipc: A61K 31/538 20060101ALI20190429BHEP
2022-03-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2022-04-13	17Q	First examination report despatched	Effective date: 20220311
2022-06-08	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602016080167 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07D0265360000 Ipc: C07C0237220000
2022-07-13	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20220608BHEP Ipc: C07D 265/36 20060101ALI20220608BHEP Ipc: C07D 417/12 20060101ALI20220608BHEP Ipc: C07D 413/12 20060101ALI20220608BHEP Ipc: C07D 231/56 20060101ALI20220608BHEP Ipc: C07D 309/34 20060101ALI20220608BHEP Ipc: C07C 237/22 20060101AFI20220608BHEP
2022-07-18	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2022-07-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2022-08-17	INTG	Intention to grant announced	Effective date: 20220719
2022-11-21	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2022-11-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2022-12-07	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2022-12-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2022-12-28	INTC	Intention to grant announced (deleted)
2023-01-04	INTG	Intention to grant announced	Effective date: 20221208
2023-03-20	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2023-05-05	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2023-05-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2023-06-07	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-06-07	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2023-06-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1574680 Country of ref document: AT Kind code of ref document: T Effective date: 20230615
2023-06-22	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602016080167 Country of ref document: DE
2023-07-12	U01	Request for unitary effect filed	Effective date: 20230607
2023-07-12	U07	Unitary effect registered	Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20230612
2023-09-25	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2023-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230907 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607
2023-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230908
2024-01-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607
2024-01-23	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231007
2024-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231007 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607
2024-02-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607
2024-03-08	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602016080167 Country of ref document: DE
2024-04-12	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2024-04-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2024-04-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20240318 Year of fee payment: 8
2024-05-01	U21	Renewal fee paid with penalty [unitary effect]	Year of fee payment: 8 Effective date: 20240326
2024-05-15	26N	No opposition filed	Effective date: 20240308
2024-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607
2024-05-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2024-07-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231031
2024-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231031
2024-10-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231022
2024-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231022